1. |
McKenzie JE, Clarke MJ, Chandler J. Why do we need Evidence-Based Methods in Cochrane? Cochrane Database Syst Rev, 2015, 7:ED000102.
|
2. |
Alan C, Richmond K, 李萃萃, 等. Cochrane协作网:21世纪第一个十年间Cochrane系统评价组内的国际性活动. 中国循证医学杂志, 2011, 11(10):1106-1110.
|
3. |
贾文琴, 杨克虎, 田金徽, 等. Cochrane系统评价发表状况调查. 中国循证医学杂志, 2009, 9(6):635-639.
|
4. |
孙晓莹, 马婧, 赵晔, 等. Cochrane系统评价现状. 中国循证儿科杂志, 2013, 8(3):237-240.
|
5. |
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. BMJ, 2009, 339:b2535.
|
6. |
Haaland B, Tan PS, de Castro Jr G, et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol, 2014, 9(6):805-811.
|
7. |
Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor:A meta-analysis. JAMA, 2014, 311(14):1430-1437.
|
8. |
Lee CK, Wu YL, Ding PN, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis. J Clin Oncol, 2015, 33(17):1958-1965.
|
9. |
Chien PF, Khan KS, Siassakos D. Registration of systematic reviews:PROSPERO. BJOG, 2012, 119(8):903-905.
|
10. |
Davies S. The importance of PROSPERO to the National Institute for Health Research. Syst Rev, 2012, 1:5.
|
11. |
杨智荣, 詹思延. PROSPERO:为非Cochrane系统评价全新打造的注册平台. 中华医学杂志, 2012, 92(6):422-425.
|
12. |
周建国, 周权, 马虎. EpiData 软件在定量系统评价数据提取中的应用. 循证医学, 2014, (6):361-362.
|
13. |
王佩鑫, 李宏田, 刘建蒙. 无对照二分类资料的Meta分析方法及Stata实现. 循证医学, 2012, 12(1):52-55, 64.
|
14. |
Booth A, Stewart L. Trusting researchers to use open trial registers such as PROSPERO responsibly. BMJ, 2013, 347:f5870.
|
15. |
Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO:an international prospective register of systematic reviews. Syst Rev, 2012, 1:2.
|
16. |
Editors TPM. Best practice in systematic reviews:the importance of protocols and registration. PLoS Med, 2011, 8(2):e1001009.
|
17. |
Kirkham JJ, Altman DG, Williamson PR. Bias due to changes in specified outcomes during the systematic review process. PLoS One, 2010, 5(3):e9810.
|
18. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
|
19. |
Tian X, Zhou JG, Zeng Z, et al. Cetuximab in patients with esophageal cancer:a systematic review and meta-analysis of randomized controlled trials. Medical Oncology, 2015, 32(4):127.
|
20. |
Zhou JG, Tian X, Wang X, et al. Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Med Oncol, 2015, 32(2):471.
|